[Effect of human recombinant granulocyte colony-stimulating factor on mouse hematopoietic and lymphoid organs].
Experiments on intact CBA/CALac mice demonstrated that single (1.25 mg/kg) and repeated (0.125 and 1.25 mg/kg, 30 days) injections of recombinant human granulocyte colony stimulation factor lead to reversible dose-dependent granulocyte lineage hyperplasia in bone marrow, regenerative neutrophilic leukocytosis, and thrombocytosis in peripheric blood and to splenic granulo-, erythro-, and thrombocytopoiesis more expressed in males.
Karpova
G V
GV
Institute of Pharmacology, Tomsk Scientific Center, Siberian Division, Russian Academy of Medical Sciences, pr. Lenina 3, Tomsk, 634028 Russia.
Fomina
T I
TI
Timina
E A
EA
Abramova
E V
EV
Masycheva
V I
VI
Pustoshilova
N M
NM
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007958:Leukocyte Count; D008221:Lymphoid Tissue / Q000187:drug effects*; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009929:Organ Size; D011994:Recombinant Proteins; D012737:Sex Factors; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013950:Thymus Gland / Q000187:drug effects
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor